Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24368981 | 1.00 | TSHR (0.35) | TSHRACACBCNR2CA1CA2 | |
| SCHEMBL25099313 | 0.84 | CA1 (0.34) | ACACBCNR2CA1CA2CA7 | |
| SCHEMBL24369855 | 0.82 | CA1 (0.37) | TSHRACACBCA1CA2CA7 | |
| SCHEMBL23924825 | 0.82 | TSHR (0.36) | TSHRCA1CA2CA7REN | |
| SCHEMBL24369856 | 0.82 | CA1 (0.37) | TSHRACACBCA1CA2CA7 | |
| SCHEMBL23924823 | 0.82 | TSHR (0.36) | TSHRCA1CA2CA7REN | |
| SCHEMBL25098434 | 0.81 | CYP2C9 (0.39) | TSHRACACBCA1CA2CA7 | |
| SCHEMBL25098432 | 0.80 | ACACB (0.41) | TSHRACACBCNR2ACACA | |
| SCHEMBL24444347 | 0.77 | TAS1R3 (0.38) | TSHRCNR2CA1CA2CA7 | |
| SCHEMBL23479934 | 0.77 | TAS1R3 (0.38) | TSHRCNR2CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | TSHR 4119/4885ACACB 53/4885CNR2 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.